
Iskra Pusic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8006957/publications.pdf Version: 2024-02-01



ISKDA DUSIC

#	Article	IF	CITATIONS
1	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213
2	Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. Bone Marrow Transplantation, 2022, 57, 302-303.	2.4	1
3	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, 2022, 139, 1177-1183.	1.4	41
4	Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature, 2022, 604, 141-145.	27.8	198
5	Decitabine salvage for <i>TP53</i> -mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. Haematologica, 2022, 107, 1709-1713.	3.5	2
6	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood, 2021, 137, 896-907.	1.4	15
7	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	1.2	24
8	SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature, 2021, 595, 421-425.	27.8	428
9	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood, 2021, 138, 2278-2289.	1.4	124
10	Beyond ruxolitinib in steroidâ€refractory acute graftâ€versusâ€host disease. British Journal of Haematology, 2021, 195, 306-307.	2.5	0
11	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
12	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research, 2021, 110, 106713.	0.8	9
13	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precision Oncology, 2021, 5, 191-203.	3.0	4
14	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. Blood, 2021, 138, 3904-3904.	1.4	0
15	The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. American Journal of Transplantation, 2020, 20, 589-592.	4.7	22
16	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	329.8	29
17	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. Cancer Discovery, 2020, 10, 1854-1871.	9.4	83
18	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica, 2020, 105, e404-e407.	3.5	16

Iskra Pusic

#	Article	IF	CITATIONS
19	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Science Translational Medicine, 2020, 12, .	12.4	41
20	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood, 2020, 135, 97-107.	1.4	56
21	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Advances, 2020, 4, 40-46.	5.2	11
22	lxazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 1612-1619.	2.0	12
23	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2002-2007.	2.0	64
24	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq0 0 methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	4.6	200
25	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. Blood, 2019, 134, 3915-3915.	1.4	6
26	Challenges in Conducting Studies in Chronic Graft-versus-Host Disease. Clinical Hematology International, 2019, 1, 36.	1.7	5
27	Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 826-831.	2.4	69
28	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	27.0	93
29	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight, 2018, 3, .	5.0	48
30	Investigating the Effects of Clonal Hematopoiesis in Healthy Marrow and Blood Donors on the Outcomes of Recipients Following Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 2180-2180.	1.4	0
31	lbrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood, 2017, 130, 2243-2250.	1.4	352
32	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. Blood, 2017, 130, 816-816.	1.4	7
33	Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1137-1141.	2.0	11
34	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leukemia Research, 2016, 49, 1-6.	0.8	31
35	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
36	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 449-455.	2.0	113

Iskra Pusic

#	Article	IF	CITATIONS
37	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 728-730.	1.3	14
38	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research, 2016, 22, 319-327.	7.0	68
39	Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Blood, 2016, 128, LBA-3-LBA-3.	1.4	12
40	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 1761-1769.	2.0	143
41	A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results. Blood, 2015, 126, 1935-1935.	1.4	2
42	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. Blood, 2015, 126, 1950-1950.	1.4	5
43	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
44	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 3144-3144.	1.4	0
45	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2014, 20, 46-52.	2.0	86
46	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 2456-2456.	1.4	1
47	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. Blood, 2014, 124, 5292-5292.	1.4	0
48	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 850-850.	1.4	0
49	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. Blood, 2013, 122, 3931-3931.	1.4	0
50	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816.	1.4	0
51	Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Current Opinion in Hematology, 2010, 17, 319-326.	2.5	124
52	Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD) Blood, 2009, 114, 3326-3326.	1.4	2
53	Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1045-1056.	2.0	319